// App-Quantinova.ai

AB0337 (2022) : BASELINE C-REACTIVE PROTEIN PREDICTS ADHERENCE TO ADALIMUMAB THERAPY AT 3 MONTHS IN AN OBSERVATIONAL COHORT OF PATIENTS WITH RHEUMATOID ARTHRITIS

Researchers

Presenter

  • A. W. Ramli

Principal Investigators

  • N. Nair

  • K. Hyrich

  • J. Isaacs

  • A. Morgan

  • D. Plant

  • A. G. Wilson

  • A. Barton

Medical Centers

  • The University of Manchester, Centre for Musculoskeletal Research, School of Biological Sciences, Manchester, United Kingdom

  • Wrightington Hospital, Wrightington, Wigan and Leigh Teaching Hospitals NHS Foundation Trust, Department of Rheumatology, Wigan, United Kingdom

  • The University of Manchester, Versus Arthritis Centre for Genetics and Genomics and Centre for Epidemiology, Manchester, United Kingdom

  • Manchester University NHS Foundation Trust, NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester, United Kingdom

  • The University of Manchester, Versus Arthritis Centre for Epidemiology, Manchester Academic Health Sciences Centre, Manchester, United Kingdom

  • Newcastle upon Tyne Hospitals NHS Foundation Trust, Translational and Clinical Research Institute, Newcastle University and Musculoskeletal Directorate, Newcastle upon Tyne, United Kingdom

  • University of Leeds, Leeds Institute of Cardiovascular and Metabolic Medicine, Leeds, United Kingdom

  • Leeds Teaching Hospitals NHS Trust and NIHR Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom

  • University College Dublin, UCD School of Medicine and Medical Science, Conway Institute, Dublin, Ireland

Locations

  • United Kingdom

  • Ireland

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Rheumatoid arthritis

Biomarkers

  • N/A

Drug/Treatment

  • Adalimumab

Outcome

  • N/A

Study Design

  • Observational

  • Multicenteric

  • Prospective

  • Cohort

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • Pfizer

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved